Delix Therapeutics raised US$100 million in an oversubscribed Series C financing. The clinical-stage neuroscience company designs neuroplastogens that promote brain repair without hallucinatory effects. The round was led by JJDC, Johnson & Johnson's corporate venture arm, and SV Health Investors' Dementia Discovery Fund.
Use of funds
The new capital will support Phase IIb proof-of-concept testing for Zalsupindole in recurrent major depressive disorder. Other pipeline candidates will also move toward clinical development. Delix plans to progress its neurodegeneration program into clinical stages.
Clinical results
In a Phase Ib trial, adults with recurrent major depressive disorder received one week of treatment with Zalsupindole. Their MADRS scores dropped by about 50% by day 8. Improvements remained through day 36, four weeks after the final dose.
Investor and board updates
Existing investors RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures, and Bail Capital participated. New investors included Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital, and YK Bioventures. Christian Jung of SV Health Investors and a JJDC representative joined Delix's board.
Delix expects to start a Phase IIb trial for Zalsupindole in the first half of 2027. The placebo-controlled study would be the first Phase II evaluation of a true neuroplastogen. Zalsupindole has shown a favorable safety and tolerability profile across more than 120 participants to date.